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Previously, we found that mutation of glutamine to proline in the endoproteolytic cleavage signal of the
PERV-C envelope (RQKK to RPKK) resulted in non-infectious vectors. Here, we show that RPKK results in
a non-infectious vector when placed in not only a PERV envelope, but also the envelope of a related
gammaretrovirus, FeLV-B. The amino acid substitutions do not prevent envelope precursor cleavage,
viral core and genome assembly, or receptor binding. Rather, the mutations result in the formation of
hyperglycosylated glycoprotein and a reduction in the reverse transcribed minus strand synthesis and
undetectable 2-LTR circular DNA in cells exposed to vectors with these mutated envelopes. Our ﬁndings
suggest novel functions associated with the cleavage signal sequence that may affect trafﬁcking through
the glycosylation machinery of the cell. Further, the glycosylation status of the envelope appears to
impact post-binding events of the viral life cycle, either membrane fusion, internalization, or reverse
transcription.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The retroviral envelope glycoprotein is encoded by the env gene
and comprises the outermost layer of the virus, providing the
functions of binding to the cellular receptor, triggering fusion with
the cell membrane, and allowing virus internalization. The retroviral
envelope glycoprotein is initially synthesized as a single polypeptide,
the env glycoprotein, which is assembled into oligomeric complexes
in the rough endoplasmic reticulum (RER), post-translationally-mod-
iﬁed, and then cleaved by a cell-encoded protease during transport to
the surface of the cell (Murakami, 2012; Swanstrom and Wills, 1997).
In the RER, the viral envelope precursor polyprotein is modiﬁed by
glycosylation and targeted to the Golgi network for further processing,
including proteolytic cleavage by the host cell furin-like protease into
the extracellular surface glycoprotein (SU) and transmembrane pro-
tein (TM). The mature envelope proteins are then transported to the
cell surface as an oligomeric complex (Checkley et al., 2011).
The viral precursor polyprotein is cleaved in the trans-Golgi net-
work by a cellular protease at the Lys/Arg-X-Lys/Arg-Arg motif (K/R‐X‐
K/R‐R, where X represents any amino acid and / indicates alternative
amino acid) which is located at the boundary between the SU and TM
(Bedgood and Stallcup, 1992; Freed et al., 1989). This highly conserved
motif, found in nearly all retroviruses (McCune et al., 1988), is also
present in orthomyxo (Stieneke-Gröber A et al., 1992) and paramyx-
ovirus (Bolt et al., 2000) envelope glycoprotein precursors.
The viral K/R-X-R/K-R motif is recognized by cellular proteolytic
enzymes, such as furin, that cleave speciﬁcally at the C-terminal basic
amino acid residue of the motif and belongs to the family of pro-
protein convertases or serine proteinases (Decroly et al., 1994;
Hallenberger et al., 1992; Klenk and Garten, 1994). The proprotein
convertases cleave secretory proteins in subcellular organelles such as
the Golgi complex, at the cell surface or in the extracellular matrix,
and in most cases, they activate cellular and viral precursor proteins
by cleavage at single or paired basic residues (Klenk and Garten,
1994). In general, the endoproteolytic cleavage signal is formed by
four amino acids consisting of either tri-basic (R-X-R/K-R), or tetra-
basic amino acid combinations (R-R/K-R/K-R). For retroviruses, the
amino acid preceding the dibasic C-terminal sequence of this site has
been considered “any type of amino acid”. It has also been demon-
strated that mutation of some amino acids within this motif may not
affect the cellular processing or the biological activity of retroviruses
(Binley et al., 2002; Dong et al., 1992; Freed et al., 1989). However it
has been shown that mutation of the C-terminal arginine of the
endoproteolytic cleavage site of the MuLV glycoprotein envelope
precursor results in a dramatic decrease in the biological activity of
the virus (Apte and Sanders, 2010; Freed and Risser, 1987). Cleavage of
the retroviral envelope glycoprotein precursor into SU and TM is
presumably essential for the post-translational activities including
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incorporation into the viral membrane, budding, maturation, receptor
binding, and membrane fusion.
While we were investigating viral determinants for human cell
tropism of porcine endogenous retrovirus (PERV), we noticed that
in addition to other residues in the C-terminal domain of SU, there
are 2 amino acid differences between PERV-C and PERV-A at the
envelope endoproteolytic cleavage signal: R-Q-K-K (GenBank acces-
sion numbers: EU440732 and DQ996276.1) and R-P-K-R (GenBank
accession no. AF130444), respectively. In order to investigate the
functional impact of these differences, we used site-directed muta-
genesis of cDNAs encoding the PERV-A or PERV-C envelopes to
generate mutant envelopes with changes in the endoproteolytic
cleavage signal. We used these mutated envelopes to evaluate
whether the mutations affect PERV envelope tropism. Surprisingly,
we found that the alteration of glutamine (Q) to proline (P) in PERV-
C (R-Q-K-K to R-P-K-K) generated a non-infectious state when
assessed using retroviral vector pseudotypes carrying the mutant
envelope (Argaw et al., 2008).
The present study expands on these initial observations by
performing more extensive mutagenesis of the cleavage signal. In
addition, we introduced similar mutations into a related gammare-
trovirus, FeLV-B, and found that the resulting phenotype was
identical. We also evaluated the mechanistic basis of the phenotype
by analyzing envelope maturation and incorporation into virions,
cell surface expression, the degree of envelope glycosylation, and the
impact of hyperglycosylation on early events of the viral life cycle.
Results and discussion
Mutation of the envelope endoproteolytic cleavage site to RPKK
renders vectors bearing mutated PERV or FeLV-B viral envelopes non-
infectious
To evaluate whether the previously identiﬁed endoproteolytic
cleavage signal of RPKK would result in a non-infectious pheno-
type in envelopes other than PERV-C, we introduced a series of
mutations into the signal sequence of the PERV-A envelope.
Similar to the PERV-C-RPKK mutant, we found that the PERV-A
envelope mutant bearing the RPKK sequences in the cleavage site
could not produce infectious particles (Fig. 1a). All other mutations
of the endoproteolytic cleavage signal, when tested in the PERV-A
envelope, resulted in retroviral vectors with infectivity titers com-
parable to vectors carrying the wild-type PERV-A sequence (Fig. 1a).
We then extended our investigation to a related gammaretro-
virus, to determine if the phenotype was transferrable to non-PERV
envelopes. Due to availability of reagents, we chose to use the FeLV-B
envelope glycoprotein. Since the endoproteolytic cleavage signal of
the FeLV-B envelope glycoprotein differs from the PERV-C envelope
in three of the four residues of the endoproteolytic cleavage signal
(R-F-R-R) (Wuensch et al., 1983), we ﬁrst needed to use site-directed
mutagenesis to determine if any intermediate changes to the
sequence would impact infectivity of resulting vectors carrying the
mutant FeLV-B envelopes. A panel of mutant FeLV-B envelopes was
prepared, retroviral vectors were generated carrying each of the
mutant envelopes, and infectivity titers were determined, as pre-
viously described (Argaw et al., 2008).
As shown in Fig. 1b, retroviral vectors carrying FeLV-B envelopes
with mutations changing the second or third residues singly or
together had infectivity titers on human 293HEK cells comparable
to those carrying the wild-type FeLV-B envelope. Vectors carrying
FeLV-B envelopes with either of two mutations (RFRk or Rqkk)
showed an intermediate phenotype, resulting in approximately
100-fold lower infectivity titers. Only retroviral vectors pseudo-
typed with the mutant FeLV-B envelope bearing the Rpkk sequence
in its cleavage signal had no detectable infectivity on 293HEK cells.
These results demonstrate that at least for PERV and FeLV-B
envelopes, the second amino acid in the 4-amino acid endoproteo-
lytic cleavage motif may require more speciﬁcity with regard to
amino acid composition for functions other than proteolytic clea-
vage, than previously understood. However, it should also be noted
that the RPKR sequence, as shown for PERV and FeLV-B does not
prevent generation of infectious vectors, demonstrating that the
second amino acid in the motif is context-dependent, suggesting
that presence of two lysines at the C-terminus of the cleavage site
may also affect infectivity. However, this is not the only factor, as we
have reported that the wild-type PERV-C envelope isolated from ST
cells has two lysines in its cleavage signal and is fully infectious.
Likewise, we show that presence of two lysines per se, in some of
the PERV-A and FeLV-B mutants did not result in loss of vector
infectivity (Fig. 1(a) and (b), mutant Rqkk), while presence of two
lysines in combination with the glutamine in the second position
(Rqkk) showed a 2-log decrease in infectivity. Previously, it was also
reported that the impact of the double lysines in the cleavage site
had been associated with reduced infectivity in murine endogenous
retrovirus isolated from BALB/C mice (Horowitz and Risser, 1985).
Fig. 1. Infectivity titers of retroviral vectors pseudotyped with wild-type or mutated PERV or FeLVB envelopes. (a) Infectivity titers of pseudotypes of PERV A and C envelopes
and PERV env mutants bearing amino acid changes in the endoproteolytic signal. Target cells are pig ST cells. CenvRQKK and AenvRPKR are wild-type signal sequences.
(b) Infectivity titers of pseudotypes of FeLV-B. RFRR is the wild-type sequence for the FeLV-B env endoproteolytic signal and the others bear mutant residues indicated in
lower case letters. Target cells are HEK293. The data shown represent the average of three replicates þ/ SE (standard error). BFU, blue forming units.
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Non-infectious viral vectors show normal viral envelope glycoprotein
synthesis
We evaluated the steps of envelope expression and cellular
processing of the FeLV-B mutants to determine what step would
account for the non-infectious phenotype when the envelope
tested encodes the endoproteolytic cleavage signal R-P-K-K. In
order to conﬁrm the formation of the precursor glycoprotein and
compare its proﬁle with the wild-type envelope, we produced the
retroviral vector pseudotypes carrying the wild-type of mutant
FeLV-B envelopes by co-transfecting the plasmids encoding the
cDNA of the envelopes and the packaging and helper vectors into
293T cells, as described previously (Argaw et al., 2008). Western
blots were performed on cell-lysates from cells expressing the
vectors pseudotyped either by wild-type or mutant FeLV-B envel-
opes. The western blot samples were characterized using the anti-
FeLV-B gp85/70 (anti-FeLV-B gp 85/70 antibody C11D8) which
detects both the precursor and mature forms of the envelope. The
85 kDa glycoprotein was observed in cells expressing the wild-
type FeLV-B envelope glycoprotein. Compared to the wild-type
envelope, the FeLV-B env mutants produced glycoproteins of
higher molecular weight (ranging approximately from 90 to
100 kDa) (Fig. 2). According to the manufacturer (Custom Mono-
clonal International, W. Sacramento, CA 95691, USA) and other
studies (Elder et al., 1987) the monoclonal antibody, anti-FeLV
gp85/gp70 (C11D8), is speciﬁc to FeLV-B gp70, cross-reacts to p15E
transmembrane protein, and can also detect higher molecular
mass precursor proteins of FeLV-B. After being characterized with
this monoclonal antibody, the FeLV-B's glycoprotein in the cell
lysates, revealed a western blot proﬁle matching the description
(Fig. 2). It had been previously suggested that the FeLVB env genes
translated from a spliced mRNA and consists of a glycosylated
protein precursor of 90 kDa. (Wuensch et al., 1983). In a related
retrovirus, MLV, immunoreactive proteins that are present in the
lysates of the cells expressing the different mutant env displayed
apparent molecular weights of 90 kDa and 70 kDa representing
endoglycosidase H (endo H) sensitive, high-mannose glycans
carrying gPr90env and mature SU (gp70) respectively (Apte and
Sanders, 2010). Therefore, the observed higher molecular weight
bands seen following the SDS PAGE gel (4–12%) analysis of the
viral glycoprotein precursors in the cell lysates of the virus
producing cells (Fig. 2) is not a new phenomenon.
Non-infectious FeLV-B mutant envelope is detectable at the cell
surface
We next evaluated whether the envelope was being expressed at
the cell surface, a prerequisite for incorporation of envelope into
virions. Again, 293T cells were co-transfected with plasmids encoding
the cDNA of the viral envelopes and the packaging and helper vectors,
as indicated above. We performed ﬂow cytometry activated cell
sorting (FACS) on cells treated ﬁrst with anti-gp85/gp70 primary
antibody followed by incubation of cells with a Fluorescein isothio-
cyanate (FITC)-conjugated anti-mouse secondary antibody. The FACS
analysis data (Fig. 3) demonstrated comparable levels of envelope on
cells transfected with plasmids expressing wild-type or mutant
envelopes, including the envelope that resulted in non-infectious
vectors, suggesting that trafﬁcking to the cell surface is not impaired
for any of the mutant envelope glycoproteins tested.
Hyperglycosylated envelope detected on vectors carrying mutant
envelopes with decreased or no detectable infectivity titer
To determine if incorporation of envelope into retroviral vectors
is impaired, we evaluated virions from supernatant of transfected
cells (as described above) by western blot with anti-FeLV-B gp85/70
and p15E antibody as well as antibodies to the MLV p30 capsid as a
control for vector particle production. The virions were puriﬁed
from the supernatant by ultracentrifugation of the supernatant on a
20% sucrose cushion, as described inMaterials and methods. Puriﬁed
virion pellets were resuspended in SDS gel loading buffer and
analyzed by reducing SDS 4–12% PAGE gels.
The western blot proﬁle showed that the mature wild-type FeLV-B
envelope glycoprotein is composed of 70 kDa and p15E proteins
(Fig. 4a). While mature SU and TM envelope proteins were detected
for all mutants analyzed (Fig. 4(a) and (b)), the migration of the SU
differed. Comparing to wild-type FeLV-B envelope glycoprotein, all
cleavage site-mutant envelope glycoproteins produced higher mole-
cular weight SU although TMwas of the expected 15 kDa size (Fig. 4(a)
and (b)). Of note, each of the three mutants that have lysine at the C-
terminus of the cleavage site showed relatively higher (approximately
85 to 90 kDa) molecular weight SU glycoprotein (Fig. 4a). As a control,
we show comparable levels of detection in all samples of the capsid
p30 protein of the helper protein MLV gagpol, demonstrating that the
fraction we puriﬁed did carry vector particles (Fig. 4a lower panel).
Interestingly, similar to our data it was reported that an arginine
substituted for a lysine in the carboxyl terminus of the cleavage site of
AKV MLV resulted in the incorporation of envelope of 100 kDa and a
100-fold reduction in the virion infectivity. In Addition, metabolic
labeling with tritiated sugars conﬁrmed that these precursors with the
100 kDa size contain complex sugar side chains (Freed and Risser,
1987). As a control, the viral env-expressing plasmid was transfected
without the helper MLVgagpol or vector plasmids. Supernatant was
collected and puriﬁed in the same manner as the other samples.
Western blot analysis was performed on this control, and while
envelope was detected in the envelope-only control, the levels were
signiﬁcantly reduced compared to the vector positive control (Fig. 4c).
To evaluate whether the higher molecular weight of SU glycopro-
tein detected for the mutant envelopes correlates with altered
glycosylation of the precursor glycoproteins in the ER or Golgi
Network pathway, we treated the puriﬁed vector particles with
PNGase-F, a glycosidase, and then determined their molecular size
by western blot with the anti-FeLV-B antibody described above.
PNGase-F is an enzyme with broad speciﬁcity that hydrolyzes high-
mannose, hybrid, and bi-, tri-, and tetra-antennary N-linked oligosac-
charides directly at the glycosyl asparagine linkage, thus liberating
polypeptides by release of N-linked oligosaccharide side chains
(Tarentino et al., 1985). Fig. 4d shows that the migration of the
envelope protein after PNGase-F treatment is essentially the same
for all mutant and wild-type FeLV-B envelopes (approximately
60 kDa). As expected, there was no change in mobility of p15E. This
result showed that the higher molecular size protein species of the
mutant envelopes was due to hyperglycosylation of the envelope. It is
well known that mature envelope glycoproteins of retroviruses are
decorated with different amount of oligosaccharides (Bedgood and
Fig. 2. Western blot analysis of cell lysates from 293T cells transfected with
plasmids encoding the wild-type and mutated FeLVB envelopes. The membrane
was probed with (a) anti-FeLV-B gp85/gp70 antibody or (b) stripped and re-probed
with human anti-β-actin antibody as the control for the loaded protein in each
sample. Numbered samples shown are: 1, Wild-type FeLV-B env; 2, RFkR; 3, RpkR;
4, Rqkk; 5, Rpkk; 6, RFRk; N, negative, supernatant from the same type of cells
transfected with plasmids encoding the env, vector, and helper genes as described
in Materials and methods. The mutated residues are shown in lower case. The side
numbers indicate the molecular weight in kilodaltons of the detected bands, based
on migration of a protein standard (Novex protein standard, Invitrogen).
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Stallcup, 1992; Geyer et al., 1990). In general the data suggested that
the endoproteolytic cleavage of the viral glycoprotein is not affected by
the mutations. In Addition, the results demonstrated the second
amino acid in the 4-amino acid endoproteolytic cleavage motif can
only be “any amino acid” from cleavage perspective as previously
suggested. However the role of this amino acid in the motif is context
dependent and provides additional functions to the env that may
affect trafﬁcking through the glycosylation machinery of the cell.
Fig. 3. Cell surface expression of wild-type (WT) or mutant viral envelopes of FeLVB as determined by ﬂow cytometry analysis of 293T cells transfected with plasmids
encoding the indicated viral envelope cDNA. WT refers to the wild-type viral envelope endoproteolytic signal sequences, RFRR, and the others are mutants in which the
lower case indicates the mutated residues.
Fig. 4. Analysis of viral vector glycoproteins before and after deglycosylation. (a) FeLV-B env or mutant envelope pseudotype viruses isolated from the supernatant of
transfected 293T cells. Viral vector glycoproteins were analyzed by Western blot by probing the membrane with anti-FeLVB gp85/gp70 anti-body (C11D8) in the top panel or
stripped and re-probed with goat anti-MLV p30 antibody in the lower panel. (b) A 15 kDa p15E (TM) band is detected by the monoclonal anti-TM antibody. (c) An env is
expressed in the absence of the gag as a control to demonstrate the level of non-incorporated env in the virions prepared for western blot analysis. (d) Analysis of the same
viral vector glycoproteins in panel a after deglycosylation with PNGase F treatment and detected with anti-FeLVB antibody. Samples numbered (1–6) are the viral envelopes
with endoproteolytic signal sequences as follows: 1, wild-type, RFRR; 2, RfkR; 3, RpkR; 4, Rqkk; 5, Rpkk; 6, RFrk; N, negative; E, env-only, env expressed in absence of helper
plasmids, Wt, wild-type FeLVB env pseudotyped retroviral vector; M, molecular weight marker. All samples were treated with reducing agent before loading. Numbers on
the side of the panels show the MW size of glycoprotein in kilodalton.
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Hyperglycosylation of the viral envelope impacts early post-binding
viral functions
To understand how hyperglycosylation of the envelope glycopro-
tein leads to a reduced or non-infectious phenotype when carried on
retroviral vector particles, we evaluated the relative ability of FeLV-B
SUmutants for binding to receptor-positive cells, 293HEK (See Fig. 5).
As shown in Fig. 5, binding was comparable for both WT and the
mutated FeLV-B SUs analyzed. As a control, we analyzed FeLV-B SU
binding to NIH 3T3 cells and showed no detectable binding, as in
previously shown studies (Hussain et al., 2011) (Fig. 5b). We next
evaluated whether the process of reverse transcriptionwas impacted.
We reasoned that lack of detection of the unintegrated DNA inter-
mediate might suggest a defect in envelope-receptor triggered fusion
Fig. 5. Cell surface binding activity of cell-secreted WT-FeLVB and mutant envelope glycoproteins. Soluble envelope glycoprotein was secreted from 293T cells transfected
with the envelope expression vector expressing the indicated env and cultured for 48 h in medium. One million 293HEK cells were incubated at 37 1C for 1 h in supernatant
without (shaded) and with (non-shaded) soluble envelope glycoprotein collected from native and transfected cells respectively. (b) A control for non-speciﬁc binding;
binding of the soluble env glycoprotein of FeLVB in a cell line, NIH 3T3, which does not express the binding receptor, comparing to human cell line that express the receptor.
Anti-FeLVB monoclonal antibody (C11D8) was used for FACS analysis. WT refers to the FeLV-B env endoproteolytic signal, RFRR, whereas the other panels show the FeLVB env
mutants bearing the indicated mutation(s). Lower case indicates mutated residues.
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(Reviewed: Overbaugh et al., 2001; Pecheur et al., 1999) or reverse
transcription. After receptor-mediated entry, reverse transcription
begins with synthesis of the minus-strand DNA, as reviewed pre-
viously (Telesnitsky and Goff, 1997). To this effect we performed PCR
analysis of the minus strand strong stop DNA from low molecular
weight DNA isolated for 18 h post-exposure to 1.0 ml of the undiluted
or 1:10 diluted vector-containing supernatant with the presence of
polybrene 8 ug/ml and DNase I 5 U/ml. As shown in Fig. 6, quanti-
tative differences were observed in the detection of the strong stop
DNA, showing the most discordance between the cells exposed to
the vector carrying the envelope with the Rpkk residues. The DNA
band intensities of the PCR products from cells infected with the
mutant envelope pseudotypes were lower than those observed for
cells exposed to the wild-type FeLV-B envelope pseudotypes (Fig. 6a).
We also used PCR to evaluate whether 2-LTR circular DNA was
formed. Detection of the 2-LTR circular form is considered a hallmark
for the entry of the pre-integration complex into the nucleus (Ellis
and Bernstein, 1989; Gao and Goff, 1999). Decreased band intensity
was observed in DNA isolated from cells exposed to the pseudotypes
carrying the FeLVB Rqkk that has a 2log lower infectivity compared
to the wt env; and there was no detectable DNA isolated from cells
exposed to the pseudotypes carrying FeLV-B Rpkk, suggesting an
absence of the circular 2-LTR form of viral DNA (Fig. 6b). As a control,
similar analysis was performed directly on vector-containing super-
natant to assess for the presence of contaminating plasmid DNA
present from transfection. No detectable PCR products were
observed; conﬁrming DNase I treatment removed contaminating
plasmid DNA (Fig. 6c). We also did western blot analysis, as described
above, of virions puriﬁed from sucrose gradients of the vector-
containing supernatant to determine if the differences in the dete-
cted reverse transcribed DNA intermediates reﬂected discrepancies
in input virus applied to the cells. As shown in Fig. 7, detectable levels
of MLV gag p30 were identical in WT and mutant vectors.
Together, these data conﬁrm that all of the mutant FeLV-B
envelopes described here were expressed, cleaved to a mature enve-
lope glycoprotein, trafﬁcked to the cell surface, incorporated into
mature virions, and released into the supernatant. However, vectors
with envelope mutants with reduced or non-infectious phenotypes
carried higher molecular weight glycoprotein species and this higher
size is attributed to the increased levels of carbohydrate moieties on
the glycoproteins. Of note, others have shown that mutations in the
cleavage sites led to the formation of higher molecular weight
glycoprotein and decreased function in infectivity of the virions
(Freed and Risser, 1987; Pinter et al., 1984; Poss et al., 1989). In
Addition, it has been shown that the envelope of dual-tropic murine
leukemia viruses was found to have the unusual property of migrating
to the cell surface without undergoing the normal glycosylation and
proteolytic processes (Kemp et al., 1981). Our data also imply that
there is not a prerequisite speciﬁc level of glycosylation for transport of
the processed glycoprotein to the cell surface and virion incorporation.
It is unclear how mutations in the endoproteolytic cleavage site
led to the formation of the hyperglycosylated envelope phenotype.
Perhaps the R-P-K-K amino acid combination in the enodoproteolytic
site affects the envelope conformation in a manner that exposes
Fig. 6. Detection of reverse transcribed DNA intermediates in cells after exposure to vector with the wild-type FeLVB envelope or hyperglycosylated non-infectious mutant
envelopes. Cells were infected with the indicated diluted (1:10) and undiluted psuedotype viruses in the presence of polybrene 8 ug/ml and DNase I 5 U/ml. Eighteen hours
post-exposure to indicated vectors gDNA was extracted, and unintegrated low molecular weight vector DNA was analyzed. (a) PCR analysis of cell lysates for minus strand
strong stop DNA, the ﬁrst detectable product of viral DNA synthesis, (b) PCR analysis of the Hirt prep for 2-LTR circularized viral DNA. Viral DNA preparation, PCR, and the gel
electrophoresis methods are described in the text. D¼diluted; U¼undiluted; Am¼Amphotropic MLV env, N¼negative; PCR¼a control for PCR process, plasmid expressing
PERV pol gene was PCR ampliﬁed in the same manner; M¼DNA size marker (PhiX174 in panel a and 1 kb DNA ladder in panel b). The numbers on the side of the panels
indicate the DNA bp size; expected sizes: 145-bp for minus strand and 603-bp for the 2-LTR DNA. (c) PCR assay to demonstrate that the DNase I treatment has removed the
contaminating plasmid DNA from the retroviral vector and cells. As a control for the DNase I removal process, cells were exposed to media spiked with 0.5 ug plasmid
expressing PERV pol gene. For PCR reaction control, 150 ng of PERV pol plasmid DNA was tested. CD¼transfection plasmids-DNA contaminated vector; Sp¼cells spiked with
known plasmid DNA; C¼positive control; M¼DNA marker.
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more sites on the envelope glycoprotein. Alternatively, previous
studies demonstrating high mannose content on murine leukemia
virus envelope glycoproteins (Kemp et al., 1981) would suggest that
transit time, glycosylation site exposure, or alternative transport
prevents action by late glycosyl processing enzymes. In Addition,
Shapiro et al. (1997) demonstrated that endogenous furin is primarily
localized in the trans Golgi network (TGN). The increased molecular
weight of certain envelope mutants in this study could result if the
mutations increased transit time in the TGN. If furin action in the
TGN is required for active virus then env proteins must pass through
the TGN. If so, this argues for either altered glycosylation site
exposure or increased transit time in the Golgi.
Finally, we also examined how the hyperglycosylated envelope
results in reduced or no infectivity. Unexpectedly, we found that the
hyperglycosylated status does not impact virus envelope binding to
receptor, but rather seems to impact some post-binding early steps
in viral entry, either membrane fusion or reverse transcription.
As described above, although we are not the ﬁrst to demonstrate
that hyperglycosylation of the viral envelopes correlates with either
reduced or lack of infectivity, we show in this study that the C-
terminal endoproteolytic cleavage signal inﬂuences glycosylation and
infectivity in an envelope-dependent manner. Further, we demon-
strated that the phenotype associated with speciﬁc amino acid
sequences can be transferred from PERV-C to PERV-A and then to
an unrelated gammaretrovirus, FeLV-B.
Together, the observations show that the enodoproteolytic motif
of the gammaretroviral envelope polyprotein may play a more
important role in overall env conformation and post-translational
modiﬁcation of gammaretroviral envelopes than was previously
recognized.
Materials and methods
Cells and culture media
All the cell lines, media and cell culture conditions used are
previously described (Argaw et al., 2008).
Construction of mutant envelope clones
The plasmids used in this study, encoding the PERV-A and
PERV-C envelope cDNAs were described previously (Gemeniano
et al., 2006). We used site-directed mutagenesis using methods
previously described to generate envelope cDNAs with mutations
that encode residue changes in the envelope endoproteolytic site
amino acids sequences R-Q-K-K of PERV-C and R-P-K-R of PERV-A,
individually or in combination (Argaw et al., 2008). Primers used
in this study for site-directed mutagenesis of PERV-A and PERV-C
are based on the reported sequences (GenBank accession numbers,
AF130444 and EU440732 respectively) (Table 1). Plasmids expres-
sing the envelope cDNA of PERV-A and PERV-C with the mutated
endoproteolytic cleavage site sequence were prepared and their
infectivity determined by pseudotyping MLV-based retroviral
vectors encoding beta-galacotosidase, as described previously
(Argaw and Wilson, 2012).
The plasmid DNA encoding the FeLV-B envelope cDNA (feline
leukemia virus Gardner-Arnstein strain subgroup B) is a gift of Dr.
John Elder at The Scripps Research Institute (La Jolla, CA) (Elder
and Mullins, 1983) (GenBank Accession number K01209.1). The
deduced amino acid residues in the endoproteolytic cleavage site
of the FeLV-B envelope glycoprotein used in this study are R-F-R-R.
The FeLV-B envelope with cleavage site mutations were made
similar to PERV envelopes by site-directed mutagenesis using the
primers listed in Table 1. The furin motif of FeLV-B (R-F-R-R) was
mutated to one of the following amino acid sequences: R-F-R-k;
R-F-k-R; R-q-k-k; R-p-k-k; R-p-k-R; and R-p-R-R. All mutated
cDNAs were sequenced using Big Dye chemistry on an ABI 310
DNA sequencer (Applied Biosystems, Foster City, CA) to conﬁrm
that site-directed mutations were present and to verify that
unscheduled mutations were absent.
Derivation of viral vector pseudotypes, and infectivity assays
Retroviral vectors expressing the designated envelope glycopro-
teins carrying wild-type or mutant envelopes were prepared by
transfection of 293T cells with a cationic liposome based reagent,
Lipofectamine 2000s transfection kit, based on the manufacturer's
instructions (Invitrogen, Carlsbad, CA USA). Brieﬂy, 3.5106 293T
cells were seeded in 100 mm20 mm style cell culture dishes one
day prior to DNA transfection. Plasmids encoding (i) cDNA of the
wild-type or mutant envelope gene, (ii) MLV-gagpol, expressing the
core and enzymatic proteins derived from Moloney MLV, and (iii)
the Moloney MLV-based retroviral vector genome encoding the
β-galactosidase genewere co-transfected into the 293T cells according
to the manufacturer's instructions (Lipofectamine 2000 reagent;
Invitrogen, Carlsbad, CA, USA). These plasmids are described pre-
viously (Gemeniano et al., 2006). The viral vector pseudotypes were
harvested for 72 h post-transfection and ﬁltered through a 0.45 mm
Fig. 7. Western blot analysis of retroviral vectors used for transduction of target
cells demonstrates comparable levels of virions. Ten milliliter of each retroviral
vector supernatant were prepared by transfection of 293T cell with the vector
encoding the different envelopes as described in Materials and methods. Three
milliliter of each retroviral vector was used for transduction of target cells for
analysis (results shown in Fig. 6). The remaining 7 ml was subjected to ultracen-
trifugation in 20% sucrose cushion, and the retroviral vector pellet was reconsti-
tuted with 1 SDS gel-loading buffer and analyzed by SDS-PAGE as described in
the Materials and methods. WT refers to the FeLV-B env endoproteolytic signal,
RFRR, whereas the other labels show the FeLVB env mutants bearing the indicated
mutation(s). Lower case indicates mutated residues. The numbers on the side of the
panel correspond with MW size of the protein in kilodalton in which 30 refers to
MLV p30.
Table 1
Sequences of the oligonucleotide primers used for site-directed mutagenesis of
PERV or FeLV-B envelopes.
Envelopes Mutants Nucleotide sequencea
PERV-C RQKK AATCATCGACAAAAGAAAGAACCCATATCT
RpKK AATCATCGACCAAAGAAAGAACCCATATCT
RpKr AATCATCGACCAAAGAGAGAACCCATATCT
PERV-A RPKR AGATATAATCGGCCAAAAAGAGAGCCCATA
RqKK AGATATAATCGGCAAAAAAAAGAGCCCATA
RPKk AGATATAATCGGCCAAAAAAAGAGCCCATA
FeLV-B RFRR AAAGCTGCCAGGTTCCGAAGAGAACCAATAT
RpRR AAAGCTGCCAGGCCACGAAGAGAACCAATAT
RFkR AAAGCTGCCAGGTTCAAAAGAGAACCAATAT
Rpkr AAAGCTGCCAGGCCAAAAAGAGAACCAATAT
RFRk AAAGCTGCCAGGTTCCGAAAAGAACCAATAT
Rqkk AAAGCTGCCAGGCAAAAGAAAGAACCAATAT
Rpkk AAAGCTGCCAGGCCAAAGAAAGAACCAATAT
a Anti-sense 50-30 complementary nucleotides were also used for the site-
directed mutagenesis reaction.
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sterile syringe ﬁlters (Whatman Inc., Florham Park, NJ). The infectivity
was then determined by seeding target cells at 1105 cells per well
in 12-well plates, one day prior to exposure to vector-containing
supernatant. The next day, medium is removed and replaced with
1.0 ml of viral vector-containing supernatant, adjusted to a ﬁnal
concentration of 8 mg/ml polybrene. Forty-eight hours post-exposure
the infectivity titer was assessed by β-galactosidase assay as pre-
viously described (Wilson and Eiden, 1991). Infectivity of each retro-
viral vector pseudotype was assayed in duplicate and the infectivity
titer was determined in three independent experiments. Results
shown are the average titers obtained in the three experiments
plus/minus the standard error.
Analysis of viral glycoproteins by western blot analysis
Following the same transfection procedures described above, in
order to concentrate the viral particles for western analysis super-
natants from transfected cells were collected in 15 ml tubes for
72 h post-transfection. The 15 ml tubes with supernatant were
centrifuged, at 300g at 4 1C for 5 min to remove dead cells and
debris. Clariﬁed supernatant was then ﬁltered through a 0.45 mm
ﬁlter (Whatman In, Florham Park, NJ) and 10 ml was transferred to
ultracentrifuge tubes (Beckman, Ultraclear Centrifuge tubes
#344058, Brea CA) containing 3 ml of 20% sucrose in TEN
(10 mM Tris pH 7.6, 1 mM EDTA, 100 mM NaCl). The tubes were
then centrifuged in an SW-41 T1 rotor (Beckman Coulter Inc., Brea,
CA) at 31000 rpm for 1 h at 4 1C. After ultra-centrifugation, the
liquid was slowly decanted. The remaining viral pellet was re-
suspended in 100 ml of cold 1 sample loading buffer consisting of
SDS (NuPAGE LDS sample buffer (4 ), Invitrogen, Carlsbad, CA)
and incubated on wet ice for 2 h. Meanwhile, the virus producer
cells from which the supernatant was harvested were lysed with
1.5 ml RIPA buffer (SIGMA, Saint Louis, Missouri, USA) with
protease inhibitor added (1 tablet of protease inhibitor per 10 ml
of RIPA buffer, Complete Minis Roche Diagnostics, Indianapolis,
IN) by rocking at 4 1C for 30 min. Cell lysates were transferred to
1.7 ml microfuge tubes and centrifuged at 11,000g for 10 min. In
order to conduct the western blot analysis, total protein concen-
tration in cell lysates was determined by BCA protein assay kits
according to manufacturer's instruction (Pierce; Thermo Scientiﬁc,
Rockford IL). Twenty to twenty ﬁve microliter of re-suspended
pellets (15 mg protein) or cell lysates representing 50 mg total
protein were prepared in sample buffer (Invitrogen, Carlsbad,
CA) with 2% reducing agent for electrophoresis. The mixtures
were incubated at 70 1C for 10 min and subjected to SDS poly-
acrylamide gel electrophoresis (SDS PAGE) from 4% to 12% Bis Tris
gel (Invitrogen, Carlsbad, CA USA) at 200 V for 40 min. The
separated proteins were transferred onto PVDF membrane (Invi-
trogen, Carlsbad, CA) at 25 V for 90 min.
FeLV-B envelope glycoproteins (both precursor and matured)
were detected with mouse anti-FeLV-B gp85/70 monoclonal anti-
body (1:1000 dilution, C11D8, Custom Monoclonals International,
W. Sacramento, CA 95691, USA). The membranes were then
incubated in goat anti-mouse IgG conjugated with horse-radish
peroxidase (1:5000 dilution, Thermo Scientiﬁc, Pierce Antibody;
Rockford, IL) for 1 h, and washed 3 times with tris-buffered saline
(pH 7.5) consisting of 0.001% Tween-20 (Bio-Rad Laboratories,
Hercules, CA). Washed membrane was treated with chemilumines-
cent substrate, Super Signal West Dura substrate (Thermo Scientiﬁc,
Rockford, IL) and then exposed to autoradiography x-ray ﬁlm
(Kodak, BioMax XAR ﬁlm, Rochester, NY) for detection of the
proteins. The C11D8 anti-FeLVB gp 85/70 monoclonal antibody
detected both gp70 and p15E glycoproteins as previously reported
(Grant et al., 1983). A separate western blot analysis was performed
for p15E TM protein as additional conﬁrmation for viral glycopro-
tein incorporation into virion particles and its proteolytic cleavage.
The envelope TM protein, p15E, was probed with mouse anti-p15E
monoclonal antibody (MCA2550, AbD SeroTec, Oxford UK) at a
1:2000 dilution. In Addition, in order to conﬁrm the proper viral
core proteins and genome assembly and maturation, the PVDF
membranes were re-stripped and probed with goat anti-MLV p30
antibody (ATCC: Antiserum against Rauscher Murine Leukemia
Virus p30; NCI HD 539; ATCC VR-1564AS-GTs).
FACS analysis to assess cell surface expression of the viral envelope gp
293T cells co-transfected with plasmids encoding the FeLV-B or
mutants and the helper gene and the packaging vector, as
speciﬁed above were dissociated from the culture dishes surface
using EDTA-based media (Cell Dissociation Solution, Non-enzy-
matic; SIGMA-ALDRICH, United Kingdom). The dissociated cells
were washed with cold PBS and ﬁxed with 2.5% formaldehyde for
30 min at room temperature. Cells are then washed twice with
cold PBS and reconstituted with 5% bovine serum albumin (BSA) to
block non-speciﬁc binding. Cells are then centrifuged at 300g for
5 min to remove excess BSA. Approximately, 1 million cells were
incubated in anti-FeLV-B gp85/70 (C11D8) primary antibody at
5 mg/ml concentration for 30 min on wet ice. Cells are then washed
twice and incubated in goat anti-mouse immunoglobulin ﬂuor-
escein isothiocyanate conjugated (FITC) secondary antibody (Jack-
son ImmunoResearch Laboratories, Inc., West Grove, PA) for
30 min before analysis by FACS assay as described previously
(Argaw and Wilson, 2012).
Glycosydase treatment of puriﬁed viral vector proteins
Evaluation of the extent of glycosylation of the WT or mutated
envelopes generated in this study was determined by removing
the carbohydrate residues using PNGase F enzymatic treatment,
based on the manufacturer's instructions (New England BioLabs,
Ipswich, MA, USA). Brieﬂy, 15 mg of puriﬁed virion proteins were
denatured at 100 1C for 10 min, and then the samples were
returned to room temperature for 10 min, followed by digestion
at 37 1C for 4 h in 1 ml of PNGase-F enzyme (10 activity units). After
separation of the deglycosylated proteins using reducing SDSPAGE,
the digested proteins were detected by western blot analysis, as
described above.
Analysis of the function of the viral envelope
In order to assess whether the viral envelope mutants were
rendered non-functional by hyperglycosylation, we analyzed the
following 2 early events of the viral life cycle:
Analysis of the receptor binding property of the viral envelopes
In order to determine the binding function of the expressed
glycoproteins, soluble viral envelope glycoprotein was prepared
and FACS analyses was performed as previously described (Argaw
and Wilson, 2012), with the following exceptions. The detection
step is done with mouse anti-FeLVB antibody (CD118) as described
above, followed by binding activity determined by FACS analysis
after the cells were stained with goat-anti-mouse secondary anti-
body conjugated with PE (Jackson ImmunoResearch laboratories
Inc., West Grove, PA). In order to assess the extent of speciﬁcity of
cell surface membrane binding, the binding of the soluble FeLV-B
SU on FeLV-B receptor-negative murine NIH 3T3 cells was exam-
ined using the same procedure as previously described (Hussain
et al., 2011). Supernatant collected from mock-transfected control
293T cells were processed in the same manner as the supernatants
from transfected cells expressing the FeLVB env glycoprotein.
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Analysis of viral DNA synthesis
To determine the mechanistic basis of the non-infectious phe-
notype of vectors carrying certain mutated envelopes, we analyzed
post-entry reverse transcription. Cells were exposed to retroviral
vectors, in the presence of polybrene 8 ug/ml, pseudotyped either
by the wild-type or the mutant FeLVB envelope. In order to remove
residual contaminating plasmid DNA present from transfection, 5 U/
ml of DNase I (Life Technologies, Grand Island NY) was added to the
supernatant before exposing to cells. After 6 h of incubation at 37 1C
the supernatant was removed and replaced with growth medium.
Eighteen hours post-exposure, infected cells were lysed and low
molecular weight (i.e., unintegrated) DNA was isolated as described
previously (Hirt, 1967) (Gao and Goff, 1999). But, before the lysis of
the cells for DNA extraction adherent cells were washed, incubated
in DNase I (15 U/ml) for 30 min in 37 1C and washed with PBS for
further removal of contaminating plasmid DNA. Then cells were
detached from the culture plates with EDTA containing cell dis-
sociation media (Sigma, St Louis, MO) that also inactivates DNase I.
The total low molecular weight DNAwas analyzed by PCR for minus
strand viral DNA transfer and the formation of circular 2- LTR viral
DNA. Since the retroviral vector genome is MLV-based, we used the
same conditions for PCR as previously described (Gao and Goff,
1999) MSS-FP (5'GCGCCAGTCCTCCGATTGACTG-30) and MSS-RP (50–
CGGGTAGTCAATCACTCAAG-30). The primers used to amplify the
MLV LTR–LTR junction were previously reported (Smith et al., 1997)
and designated as MR578 and MR4091. At the same time, viral
vectors pseudotyped with the amphotropic MLV (A-MLV) env were
prepared and treated similarly, to serve as a control for the assays.
A-MLV envelope expressing vector, pVack Ampho (Stratagene, La
Jolla, CA) and the following 2 primers from the env gene were used
for PCR ampliﬁcation of a segment of the gene: a) A-MlvEnvFw, 50-
actggagatagactactagc-30; b) A-MlvEnvRev, 50-aggaatagcaaatctaggct-
30. PCR conditions for amplifying the Minus strand strong stop DNA
and the 2-LTR junctions were: holding for a cycle of 3 min at 94 1C,
followed by 30 thermo-cycles consisting of a cycle at 94 1C for 30 s,
56 1C for 30 s, and 72 1C for 1 min. A pair of PCR primers and
plasmid DNA encoding the pol gene of PERV is used as a control for
PCR reaction and conditions (Argaw et al., 2002). In order to
conﬁrm the removal of contaminating plasmid DNA, target cells
in 12 wells plate were exposed to 1 ml of FeLVB env pseudotyped
retroviral vector supernatant treated with polybrene 8 ug/ml and
DNase I 5 U/ml, and incubated for 6 h at 37 1C before media was
replenished. Eighteen hours post-exposure the cells were treated
with 15 U/ml DNase I for 30 min, detached with dissociation media,
and then gDNA was extracted. The gDNA was tested by PCR for
FeLVB env gene sequences using relevant primers speciﬁc to FeLVB
env gene. To validate the DNase I removal process, target cells were
exposed to media spiked with 0.5 ug plasmid expressing other
gene, PERV pol, and treated in the same manner as the test samples
and tested for PERV pol sequence by PCR. For PCR reaction control,
150 ng of PERV pol plasmid DNA was tested for pol sequence by the
same PCR reaction.
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